Literature DB >> 7527759

Diuretic strategies in patients with renal failure.

S K Swan1.   

Abstract

A thorough understanding of the clinical pharmacology of diuretic agents, particularly loop diuretics, is crucial in patients with abnormal (and those with normal) renal function. Renal insufficiency represents a pathophysiological state characterised by diuretic resistance. Diuretic resistance is defined as a diminished pharmacological response, or diminished natriuresis, to a given dose of a diuretic. The phenomenon of diuretic resistance is demonstrated by a shift in the dose-response curve relating urinary diuretic excretion rates (dose) with sodium excretion (response). Pharmacokinetic factors underlie the diuretic resistance observed in patients with renal failure. Diminished renal blood flow and sodium filtration, accumulation of organic acids that inhibit tubular secretion of the diuretic, and inadequate cumulative sodium excretion to meet patients' needs contribute to the diuretic-resistant state. In contrast, the pharmacological response of remnant (i.e. remaining) nephrons to diuretic agents remains intact. The time course of delivery of diuretics to their intraluminal site of action is an independent determinant of natriuretic response. An administration regimen that continuously maintains effective rates of excretion of diuretics into the urine would be expected to cause a greater overall natriuretic effect than the same amount of diuretic administered in intermittent doses. Thus, diuretic administration strategies that take account of the altered pharmacological responses in patients with renal failure are necessary to provide effective and safe treatment. Additionally, such strategies warrant revision by the prescribing physician as renal function changes over time.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7527759     DOI: 10.2165/00003495-199448030-00005

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  14 in total

1.  Tubular chloride transport and the mode of action of some diuretics.

Authors:  M B Burg
Journal:  Kidney Int       Date:  1976-02       Impact factor: 10.612

Review 2.  Regulation of renal ion transport and cell growth by sodium.

Authors:  B A Stanton; B Kaissling
Journal:  Am J Physiol       Date:  1989-07

3.  Intratubular albumin blunts the response to furosemide-A mechanism for diuretic resistance in the nephrotic syndrome.

Authors:  K A Kirchner; J R Voelker; D C Brater
Journal:  J Pharmacol Exp Ther       Date:  1990-03       Impact factor: 4.030

4.  The influence of sodium and potassium supplements on the diuretic responses to frusemide administration in normal subjects.

Authors:  R A Branch; E Cole; C E Horth; L Jackson; L E Ramsay; J Shelton
Journal:  Br J Pharmacol       Date:  1978-10       Impact factor: 8.739

Review 5.  The physiologic basis of diuretic synergism: its role in treating diuretic resistance.

Authors:  D H Ellison
Journal:  Ann Intern Med       Date:  1991-05-15       Impact factor: 25.391

6.  Depression of renal clearance of furosemide in man by azotemia.

Authors:  H J Rose; K O'Malley; A W Pruitt
Journal:  Clin Pharmacol Ther       Date:  1977-02       Impact factor: 6.875

7.  Effects of piretanide in normal subjects.

Authors:  D C Brater; S Anderson; B Baird; S Kaojarern
Journal:  Clin Pharmacol Ther       Date:  1983-09       Impact factor: 6.875

8.  Effects of the rate and composition of fluid replacement on the pharmacokinetics and pharmacodynamics of intravenous furosemide.

Authors:  T Li; M G Lee; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

9.  Comparison of loop diuretics in patients with chronic renal insufficiency.

Authors:  J R Voelker; D Cartwright-Brown; S Anderson; J Leinfelder; D A Sica; J P Kokko; D C Brater
Journal:  Kidney Int       Date:  1987-10       Impact factor: 10.612

10.  Clinical pharmacology of torasemide, a new loop diuretic.

Authors:  D C Brater; J Leinfelder; S A Anderson
Journal:  Clin Pharmacol Ther       Date:  1987-08       Impact factor: 6.875

View more
  6 in total

Review 1.  A practical guide to the management of hypertension in renal transplant recipients.

Authors:  A J Olyaei; A M deMattos; W M Bennett
Journal:  Drugs       Date:  1999-12       Impact factor: 9.546

2.  Evolving treatment strategies for management of cardiorenal syndrome.

Authors:  Sanjay Dandamudi; Horng H Chen
Journal:  Curr Treat Options Cardiovasc Med       Date:  2011-12

3.  Antihypertensive agents and renal transplantation.

Authors:  G Vergoulas
Journal:  Hippokratia       Date:  2007-01       Impact factor: 0.471

4.  Low albumin levels and high impedance ratio as risk factors for worsening kidney function during hospitalization of decompensated heart failure patients.

Authors:  Adrian Valdespino-Trejo; Arturo Orea-Tejeda; Lilia Castillo-Martínez; Candace Keirns-Davis; Alvaro Montañez-Orozco; Gerson Ortíz-Suárez; D Alejandro Delgado-Pérez; Bianka Marquez-Zepeda
Journal:  Exp Clin Cardiol       Date:  2013

Review 5.  Cardiorenal syndrome in children with heart failure.

Authors:  Jack F Price; Stuart L Goldstein
Journal:  Curr Heart Fail Rep       Date:  2009-09

6.  Acute and acute-on-chronic kidney injury of patients with decompensated heart failure: impact on outcomes.

Authors:  Qiugen Zhou; Chunmei Zhao; Di Xie; Dingli Xu; Jianping Bin; Pingyan Chen; Min Liang; Xun Zhang; Fanfan Hou
Journal:  BMC Nephrol       Date:  2012-07-02       Impact factor: 2.388

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.